According to the results of CheckMate-649 [5], patients with GC who received Nivolumab in combination with chemotherapy had better clinical benefits than those treated with chemotherapy alone, regardless of the PD-L1 Combined Positive Score (CPS). This evidence concerns the gene CD274 and gastric cancer.